XOMA Royalty Corp.

根据药明康德数据库统计，截至2026年8月27日，2026年8月全球生物医药领域共计完成107起融资活动，累计公开披露的融资总额超过42亿美元。其中，有21家专注于开发创新疗法的公司单轮融资额达到或超过了5000万美元。这些公司不仅涵盖了传统的小分子药物研发，还涉及多种新分子疗法领域。在接下来的内容中，我们将依据公开资料为读者介绍其中5家获得大额融资的创新药开发公司，探讨它们所开发的创新疗法以及这些疗法未来可能带来的患者福祉。 BlossomHill Therapeutics：以大环化学突破肿瘤耐药难题 BlossomHill Therapeutics日前宣布完成首次公开募股（IPO），募集资金总额约1.5亿美元。此次募集资金将主要用于推进核心肿瘤管线的临床开发，并支持其他候选药物和发现项目。 BlossomHill是一家专注于精准肿瘤药物开发的临床阶段生物医药公司，其研发策略的一大特点是利用大环化学（macrocyclic chemistry）和构象选择性设计，开发能够解决耐药问题的小分子药物。公司的主要候选药物BH-30643是一款非共价、大环、具有脑渗透能力的突变选择性泛EGFR抑制剂，旨在靶向包括C797S和T790M在内的多种EGFR耐药突变，同时尽量减少对野生型EGFR的抑制。目前，该药正在开展1/2期SOLARA临床试验，评估其治疗携带EGFR或HER2突变的非小细胞肺癌患者的潜力。 公司的另一款临床阶段候选药物BH-30236是一款大环CDC样激酶（CLK）抑制剂，目前正在开展1/1b期临床研究，用于治疗复发或难治性急性髓系白血病（AML）和较高风险骨髓增生异常综合征（HR-MDS），包括单药治疗以及与venetoclax联合治疗。此外，公司正在推进BH-501284，这是一款采用新型化学骨架设计的非共价、选择性泛KRAS Switch II抑制剂，目前处于临床前开发阶段。 崔景荣（J. Jean Cui）博士是BlossomHill Therapeutics的科学创始人、总裁兼首席执行官。她拥有超过29年的药物研发经验。在创立BlossomHill之前，崔博士曾担任Turning Point Therapeutics科学创始人兼首席科学官，并参与推动公司于2019年上市，Turning Point随后于2022年被百时美施贵宝（Bristol Myers Squibb）以约41亿美元收购。更早之前，她曾在辉瑞（Pfizer）从事药物研发。崔博士参与领导设计和开发的药物包括repotrectinib、crizotinib和lorlatinib等已获FDA批准的抗肿瘤药物。 Latigo Biotherapeutics：以NaV1.8精准抑制探索非阿片镇痛 Latigo Biotherapeutics于8月完成规模扩大的IPO，募集资金总额约3.46亿美元。本次IPO募集资金将主要支持其非阿片类疼痛治疗管线的后期临床开发。 Latigo是一家专注于开发非阿片类疼痛治疗药物的临床阶段公司。公司的核心研发思路是精准调控外周疼痛信号，在缓解疼痛的同时尽可能避免传统阿片药物所带来的成瘾、呼吸抑制等中枢神经系统相关风险。 其主要候选药物LTG-001是一款口服、高选择性NaV1.8电压门控钠离子通道抑制剂。NaV1.8主要表达于负责传递疼痛信号的外周伤害性感觉神经元，因此被视为开发非阿片镇痛药的重要靶点。LTG-001已于2025年获得美国FDA快速通道资格。2026年公布的一项针对腹部成形术后急性疼痛患者的2b期临床试验中，高剂量LTG-001达到主要终点，并显示快速且具有临床意义的镇痛作用以及减少阿片类药物使用的潜力，相关结果于7月发表在《新英格兰医学杂志》。公司计划于2026年下半年启动拇外翻术后疼痛3期研究以及一项开放标签3期安全性研究。 Latigo还在开发下一代NaV1.8抑制剂LTG-321，用于慢性肌肉骨骼疼痛等疾病。LTG-321与LTG-001具有不同的化学结构，公司希望通过进一步优化药代动力学和药效学特征，实现更低剂量、每日一次给药。公司此前公布的1期研究数据显示，LTG-321单次给药24小时后仍可观察到明显的药效学活性。 Nima Farzan先生是Latigo Biotherapeutics的总裁兼首席执行官，拥有超过20年的生物医药行业经验。在加入Latigo之前，他曾担任精准肿瘤公司Kinnate Biopharma首席执行官，并带领该公司完成约2.7亿美元IPO。此前，他还曾担任疫苗公司PaxVax总裁兼首席执行官，期间参与推动Vaxchora获得FDA批准。Farzan先生此前还曾在诺华（Novartis）、DoubleTwist以及波士顿咨询公司（BCG）任职。 LifeMine Therapeutics：从真菌遗传信息中“挖掘”新药 LifeMine Therapeutics于8月披露两轮合计2.63亿美元融资，其中包括于2026年7月完成的1.88亿美元E轮融资，以及此前于2025年第四季度完成的7500万美元D轮融资。新资金将主要用于推进公司核心临床项目以及进一步拓展其药物发现平台。 LifeMine的特点并不是从传统合成化合物库中寻找药物，而是尝试利用自然界长期进化形成的化学多样性发现新药。公司将这一模式称为“自上而下药物发现”（Top-Down Drug Discovery）：通过系统分析真菌的遗传信息，寻找由基因编码、具有药理活性的天然小分子，并结合数据科学、机器学习、高通量微生物学和自动化技术，将这些天然化学线索转化为候选药物。LifeMine还与GSK达成合作，利用这一平台针对多个疾病靶点发现新的小分子先导化合物。 该公司的主要候选药物LIFE-001是一款结构和作用机制均具有差异化特征的钙调神经磷酸酶激活抑制剂（calcineurin activation inhibitor，CNai）。传统的钙调神经磷酸酶抑制剂需要首先结合免疫亲和蛋白（immunophilin），再间接抑制钙调神经磷酸酶；LIFE-001则被设计为一种不依赖免疫亲和蛋白、直接作用于钙调神经磷酸酶的抑制剂，并采用长效注射剂型。目前LIFE-001正在开展首次人体1期临床研究。公司计划于2027年初分别启动肾移植患者2期研究以及胰岛细胞移植患者1b期研究。 Gregory Verdine博士是LifeMine Therapeutics的联合创始人、总裁兼首席执行官，也是化学生物学和新型药物模式领域的资深科学家。他曾长期担任哈佛大学和哈佛医学院教授，在化学生物学及新型治疗分子开发领域开展研究，并参与创立或共同创立Wave Life Sciences、Warp Drive Bio、FogPharma和Enanta Pharmaceuticals等多家生物医药公司。 Vaderis Therapeutics：以变构AKT抑制剂治疗遗传性出血性毛细血管扩张症 Vaderis Therapeutics于8月宣布完成一笔超额认购的约1.52亿美元B轮融资。此次融资与公司启动engasertib全球3期HEROIC临床试验同步公布，资金预计可支持该项目推进至监管申报阶段，并可能覆盖其在美国获批前的开发活动。 Vaderis专注于开发遗传性出血性毛细血管扩张症（HHT）的靶向疗法。HHT是一种遗传性血管疾病，患者由于血管生成和成熟过程异常，可出现反复鼻出血、胃肠道出血、贫血以及动静脉畸形等表现。目前全球尚无获批用于治疗HHT的药物。 公司的主要候选药物engasertib（VAD044）是一款每日一次口服、选择性变构AKT1/2抑制剂。HHT相关基因异常可导致AKT信号通路过度激活，从而促进异常血管生长；engasertib旨在通过调节这一病理通路，从疾病机制层面减少异常血管形成。此前公布的概念验证临床研究及长期扩展研究结果显示，engasertib在12周治疗期内呈现剂量依赖性的临床改善，部分疗效在持续治疗12个月后仍得到维持。目前，公司已启动全球3期HEROIC研究。 Azmi Nabulsi博士现任Vaderis Therapeutics总裁兼首席执行官。在加入Vaderis之前，他曾联合创立Phathom Pharmaceuticals并担任首席运营官，参与推动该公司的胃肠疾病药物研发及商业化工作。在此之前，Nabulsi博士曾在武田（Takeda）等大型医药企业担任多个研发领导职务，在药物开发、临床研发和企业运营方面拥有丰富经验。 Avere Therapeutics：以口服环肽切入已被生物制品验证的IL-23通路 Avere Therapeutics于8月宣布一笔5亿美元私募融资，本次融资与此前宣布的3.2亿美元私募融资合计，预计可支持公司的运营计划至2029年。 Avere的主要候选药物AVR-001体现了一种值得关注的口服药物创新思路。AVR-001并不是传统意义上的小分子，而是一款口服环肽IL-23受体拮抗剂。它所代表的产品逻辑与新一代小分子研发具有明显共通性：IL-23通路已经被多款抗体生物制品充分验证，而Avere希望利用具有口服潜力的分子直接阻断IL-23受体，从而将这一成熟治疗机制转化为更加便捷的给药方式。 AVR-001最初由翰森制药（Hansoh Pharmaceutical Group）开发，Avere获得了该药大中华区以外的开发和商业化权益。该药正在开发用于银屑病、溃疡性结肠炎等免疫介导疾病。此前1b期银屑病研究已经获得临床数据，公司计划于2027年初启动2b期银屑病临床研究，预计于2028年上半年获得主要结果，后续还计划推进银屑病3期研究以及溃疡性结肠炎2b期研究。公司希望最终将AVR-001开发为具有每周一次口服给药潜力的IL-23通路治疗药物。 Andrew Cheng博士现任Avere Therapeutics总裁、首席执行官兼董事长。在加入Avere之前，他曾担任Akero Therapeutics总裁兼首席执行官，并带领公司从私募融资阶段完成IPO和后续临床开发。Akero于2025年被诺和诺德（Novo Nordisk）收购。在此之前，Cheng博士曾在吉利德科学（Gilead Sciences）工作近20年，最后担任首席医学官，并参与领导多款药物的全球临床开发及监管申报。 多技术路径体外筛选助力新一代小分子药物发现 截至2026年8月27日，根据对今年单笔融资金额不低于5000万美元的生物医药融资事件梳理，至少有50家布局小分子药物开发的公司宣布或完成大额融资或IPO，约占相关公司的三分之一。从今年获得大额资本支持的项目来看，拓展可探索的化学空间，以及提高对靶点、作用位点和组织暴露的精准控制，正成为新一轮小分子创新的两个重要方向。 这一趋势在本月几笔具有代表性的大额融资中也得到体现。首先，创新正在从经典的线性小分子骨架走向更广阔的化学空间。BlossomHill通过大环结构获得构象选择性、脑渗透能力以及对复杂耐药突变的覆盖；LifeMine则直接从真菌遗传信息及天然产物化学空间中寻找人类尚未充分探索的分子骨架。两家公司虽然采用完全不同的方法，却都在回答同一个问题——如何突破传统化合物库已经被充分探索的边界。 其次，小分子研发越来越强调精准药理学而不仅仅是“更强的抑制作用”。Latigo通过高度选择性抑制主要分布于外周痛觉神经元的NaV1.8，希望实现镇痛作用与中枢副作用的分离；Vaderis则利用变构方式调控AKT1/2信号，从疾病机制层面干预异常血管生长。这些项目体现出小分子创新正在进一步走向靶点选择性、作用位点、组织暴露和靶点调控程度的精细化设计。 随着小分子药物不断向新的化学空间、靶点类型和作用机制拓展，如何针对不同靶点找到高质量苗头化合物，并快速验证其成药潜力，正在成为早期药物发现的重要挑战。 药明康德生物学业务平台（WuXi Biology）构建了覆盖多技术路径的体外筛选（in vitro screening）综合平台，旨在为创新药物发现提供高效、可靠且可扩展的苗头化合物识别解决方案，加速从靶点验证迈向先导化合物发现的关键阶段。平台整合高通量筛选（HTS）、片段筛选、DNA编码化合物库（DEL）、亲和选择质谱（ASMS）、展示技术以及虚拟筛选等多种前沿技术，可根据不同靶点特性和项目需求灵活组合或并行应用，实现对小分子及新型治疗模式分子的全面筛选支持。 依托超过15年的筛选经验与标准化实验体系，WuXi Biology能够开展与研究目标高度匹配的苗头化合物发现项目，并结合专有化合物库与验证体系，提高筛选结果的精准性与可推进性。平台提供涵盖酶、激酶、GPCR、离子通道及转录因子等多类型靶点的生化与细胞水平检测，同时支持荧光、TR-FRET、发光、放射性检测、基因表达分析及质谱等多样化检测方式，满足不同作用机制研究需求。一体式自动化系统可实现每周超过100万数据点的筛选通量，初筛平均周期约2周，有效缩短早期研发时间。 此外，平台还结合高内涵筛选（HCS）技术，在复杂细胞体系中实现多参数表型分析，可同步评估细胞功能、毒性及作用机制，为后续体内研究提供更具转化价值的数据支持。通过与药明康德一体化药物发现体系深度协同，WuXi Biology体外筛选能力可无缝衔接命中确认、先导优化及候选化合物筛选流程，帮助合作伙伴更高效地探索化学空间、降低研发风险，并加速创新分子向临床阶段推进。 参考资料： [1] BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering. Retrieved August 25, 2026, from https://ir.bhtherapeutics.com/news-releases/news-release-details/blossomhill-therapeutics-announces-pricing-upsized-150-million [2] Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering. Retrieved August 25, 2026, from https://latigobio.com/latigo-biotherapeutics-announces-pricing-of-upsized-345-6-million-initial-public-offering/ [3] LifeMine Raises $263 Million to Accelerate the Clinical Development of LIFE-001, a Structurally and Mechanistically Novel Calcineurin Activation Inhibitor Designed to Transform Organ Transplantation. Retrieved August 25, 2026, from https://www.businesswire.com/news/home/20260805424364/en/LifeMine-Raises-%24263-Million-to-Accelerate-the-Clinical-Development-of-LIFE-001-a-Structurally-and-Mechanistically-Novel-Calcineurin-Activation-Inhibitor-Designed-to-Transform-Organ-Transplantation [4] Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia. Retrieved August 25, 2026, from https://www.prnewswire.com/news-releases/vaderis-therapeutics-announces-oversubscribed-152-million-series-b-financing-and-initiation-of-the-global-phase-3-heroic-study-of-engasertib-for-hereditary-hemorrhagic-telangiectasia-302845188.html [5] Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001. Retrieved August 25, 2026, from https://www.prnewswire.com/news-releases/avere-therapeutics-announces-500-million-private-placement-to-support-development-of-once-weekly-oral-il-23-therapy-avr-001-302846694.html 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。 版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。

The oncolytic virus cancer therapy market is poised for significant growth, driven by increasing research and development of genetically engineered viruses that selectively target and destroy cancer cells while stimulating anti-tumor immune responses. The expanding clinical pipeline of therapies such as Cretostimogene grenadenorepvec (CG Oncology), CAN-2409 (Candel Therapeutics), AdAPT-001 (EpicentRx), LOAd703 (Lokon Pharma), RP1 (Replimune), VG 161 (Virogin Biotech), RP2 (Replimune), and others are expected to further accelerate market growth.. 溶瘤病毒癌症治疗市场有望实现显著增长，其驱动力在于针对基因工程病毒的研發日益增加，这些病毒能够选择性靶向并摧毁癌细胞，同时激发抗肿瘤免疫反应。随着Cretostimogene grenadenorepvec（CG Oncology公司）、CAN-2409（Candel Therapeutics公司）、AdAPT-001（EpicentRx公司）、LOAd703（Lokon Pharma公司）、RP1（Replimune公司）、VG 161（Virogin Biotech公司）、RP2（Replimune公司）等疗法临床管线的不断扩展，预计将进一步加速市场增长。LAS VEGAS 拉斯维加斯, ，Aug. 26, 2026 2026年8月26日/PRNewswire/ --DelveInsight's Oncolytic Virus Cancer Therapy Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Melanoma, Biliary Tract Cancer, Head and Neck Cancer, Pancreatic Cancer, NSCLC, Hepatocellular Carcinoma, Breast Cancer, Prostate Cancer, Brain Cancer, Bladder Cancer, Ovarian Cancer, and others. /PRNewswire/ -- DelveInsight的《溶瘤病毒癌症治疗市场规模、目标人群、竞争格局与市场预测》报告全面剖析了当前的治疗实践和可覆盖的患者人群，涵盖黑色素瘤、胆道癌、头颈癌、胰腺癌、非小细胞肺癌、肝细胞癌、乳腺癌、前列腺癌、脑癌、膀胱癌、卵巢癌等主要适应症及其他适应症。The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging oncolytic virus cancer therapy, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets (the US, EU4, UK, and Japan).. 所选适应症基于已获批的疗法和正在进行的研发管线活动。报告还提供了对新兴溶瘤病毒癌症疗法的洞察、各疗法的市场份额，以及2022年至2036年期间当前和预测的市场规模，并按领先市场（美国、欧盟四国、英国和日本）进行细分。Key Takeaways from the Oncolytic Virus Cancer Therapy Market Report 溶瘤病毒癌症治疗市场报告的关键要点The market size for oncolytic virus cancer therapywas found to be 溶瘤病毒癌症疗法的市场规模被发现为USD 177 million 1.77亿美元in the 7MM in 2025. 在2025年的7MM中。The United States accounted for the largest oncolytic virus immunotherapy marketsize of the total market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. 2025年，在七大主要市场（7MM）中，美国占溶瘤病毒免疫疗法市场规模的份额最大，高于其他主要市场，包括欧盟四国（德国、法国、意大利和西班牙）、英国和日本。The report provides the total potential number of patients in the indications, such as 该报告提供了各适应症中潜在患者总数，例如Melanoma, Biliary Tract Cancer, Head and Neck Cancer, Pancreatic Cancer, NSCLC, Hepatocellular Carcinoma, Breast Cancer, Prostate Cancer, Brain Cancer, Bladder Cancer, Ovarian Cancer, and others 黑色素瘤、胆道癌、头颈癌、胰腺癌、非小细胞肺癌、肝细胞癌、乳腺癌、前列腺癌、脑癌、膀胱癌、卵巢癌等. 。Oncolytic virus therapies are primarily being developed to treat cancers in relapsed refractory settings. Consequently, these therapies could address nearly 溶瘤病毒疗法主要正在被开发用于治疗复发难治性癌症。因此，这些疗法可以解决几乎20% 百分之二十of all cancer cases, providing a significant treatable patient pool. 占所有癌症病例的很大一部分，提供了可观的可治疗患者群体。Leading oncolytic virus companies, such as 领先的溶瘤病毒公司，例如CG Oncology, Candel Therapeutics, EpicentRx, Lokon Pharma, Replimune, Virogin Biotech, Binhui Bio, Genelux, Imugene, BioInvent, Transgene, Oncolytics Biotech, CG Oncology、Candel Therapeutics、EpicentRx、Lokon Pharma、Replimune、Virogin Biotech、滨会生物、Genelux、Imugene、BioInvent、Transgene、Oncolytics Biotech，and others, are developing novel oncolytic virus cancer therapiesthat can be available in the oncolytic virus therapy marketin the coming years. 以及其他机构正在开发新型溶瘤病毒癌症疗法，这些疗法有望在未来几年内进入溶瘤病毒治疗市场。Some of the key oncolytic virus cancer therapiesin clinical trials include 临床试验中一些关键的溶瘤病毒癌症疗法包括Cretostimogene grenadenorepvec, CAN-2409, AdAPT-001, LOAd703, RP1, RP2, VG 161, BS001, Olvi-Vec, CF33, BT-001, TG6050, Pelareorep, Cretostimogene grenadenorepvec、CAN-2409、AdAPT-001、LOAd703、RP1、RP2、VG 161、BS001、Olvi-Vec、CF33、BT-001、TG6050、Pelareorep，and others. 以及其他。Discover real-time oncolytic virus analysis @ 发现实时溶瘤病毒分析 @https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-marketKey Factors Driving the Oncolytic Virus Cancer Therapy Market 推动溶瘤病毒癌症治疗市场的关键因素Growing Adoption of Novel Cancer Immunotherapies: 新型癌症免疫疗法的日益普及：The increasing shift toward innovative immuno-oncology approaches is driving interest in oncolytic virus therapies. These treatments can selectively infect and destroy tumor cells while also stimulating broader antitumor immune responses. 日益向创新免疫肿瘤学方法的转变，正推动人们对溶瘤病毒疗法的兴趣。这些疗法能够选择性感染并摧毁肿瘤细胞，同时激发更广泛的抗肿瘤免疫反应。Rising Cancer Burden Worldwide: 全球癌症负担日益加重：The growing incidence of cancer and the need for more effective treatment options are creating demand for alternative therapeutic modalities. Oncolytic viruses offer a promising approach, particularly for patients with advanced or treatment-resistant cancers. 癌症发病率的不断上升以及对更有效治疗方案的需求，正在推动对替代性治疗方式的需求。溶瘤病毒提供了一种颇具前景的治疗途径，尤其适用于晚期或耐药性癌症患者。Advancements in Viral Engineering Technologies: 病毒工程技术进展：Progress in genetic engineering is enabling the development of more targeted and potent oncolytic viruses. Researchers can modify viral platforms to improve tumor selectivity, enhance immune activation, and deliver therapeutic genes directly to cancer cells. 基因工程的进步使得开发更具靶向性和更强效的溶瘤病毒成为可能。研究人员可以对病毒平台进行改造，以提高肿瘤选择性、增强免疫激活，并将治疗基因直接递送至癌细胞。Increasing Clinical Development and Pipeline Activity: 临床开发及管线活动日益增加：Pharmaceutical and biotechnology companies are expanding their oncolytic virus therapy pipelines across multiple tumor types. Growing clinical trial activity of therapies such as 制药和生物技术公司正在扩展其溶瘤病毒疗法在多种肿瘤类型中的研发管线。诸如以下疗法的临床试验活动日益增多：Cretostimogene grenadenorepvec 克雷托刺激基因格瑞纳多诺普维克(CG Oncology), (CG Oncology),CAN-2409 CAN-2409(Candel Therapeutics), （Candel Therapeutics）AdAPT-001 AdAPT-001(EpicentRx), （EpicentRx）LOAd703 LOAd703(Lokon Pharma), （Lokon Pharma）RP1 RP1(Replimune), （Replimune），VG 161 VG 161(Virogin Biotech), and others, andencouraging efficacy data are supporting greater investment and market interest. （Virogin Biotech）等公司，以及令人鼓舞的疗效数据正推动着更多的投资和市场关注。Aparna Thakur, an oncology expert at DelveInsight, said that with ongoing advancements and strategic collaborations, oncolytic viruses are positioned to play a pivotal role in the future of oncology, providing patients with new hope and facilitating the development of more effective and personalized cancer therapies.. DelveInsight 的肿瘤学专家阿帕尔纳·塔库尔（Aparna Thakur）表示，随着持续的技术进步和战略合作，溶瘤病毒有望在肿瘤学的未来发展中发挥关键作用，为患者带来新希望，并推动更有效、更个性化的癌症疗法的开发。Oncolytic Virus Cancer Therapy Market Analysis 溶瘤病毒癌症治疗市场分析报告Oncolytic viruses represent a promising immunotherapeutic approach in which viruses are used to selectively infect and eliminate cancer cells. Beyond their inherent tumor-targeting properties, these viruses can be genetically engineered to introduce therapeutic genes into malignant cells, thereby enhancing their antitumor activity.. 溶瘤病毒代表了一种前景广阔的免疫治疗方法，通过利用病毒选择性感染并清除癌细胞。除了其固有的肿瘤靶向特性外，这些病毒还可以通过基因工程改造，将治疗性基因导入恶性肿瘤细胞，从而增强其抗肿瘤活性。In 2015, 2015年，IMLYGIC IMLYGICbecame the first oncolytic virus to receive U.S. FDA approval for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma that had recurred following initial surgery. 成为首个获得美国食品药品监督管理局（FDA）批准、用于局部治疗初治手术后复发的黑色素瘤患者不可切除的皮肤、皮下及淋巴结病变的溶瘤病毒。Subsequently, in June 2021, 随后，在2021年6月，DELYTACT 德立他克(teserpaturev/G47∆; Daiichi Sankyo) obtained conditional and time-limited approval from Japan's Ministry of Health, Labor and Welfare (MHLW) for the treatment of patients with malignant glioma. (teserpaturev/G47∆；第一三共) 获得了日本厚生劳动省（MHLW）针对恶性胶质瘤患者治疗的有条件且限时批准。A diverse range of oncolytic virus platforms is currently being investigated in clinical development, including adenoviruses, herpes simplex viruses, Maraba viruses, measles viruses, Newcastle disease viruses, picornaviruses, reoviruses, vaccinia viruses, vesicular stomatitis viruses, and other viral platforms.. 目前，多种溶瘤病毒平台正处于临床开发研究阶段，包括腺病毒、单纯疱疹病毒、马拉巴病毒、麻疹病毒、新城疫病毒、小核糖核酸病毒、呼肠孤病毒、痘苗病毒、水疱性口炎病毒以及其他病毒平台。Encouraging clinical trial outcomes across multiple cancer types, including melanoma, bladder cancer, biliary tract cancer (BTC), glioblastoma, ovarian cancer, pancreatic cancer, and other solid tumors, have further accelerated interest in and development of these emerging therapeutic modalities. 在包括黑色素瘤、膀胱癌、胆道癌（BTC）、胶质母细胞瘤、卵巢癌、胰腺癌及其他实体瘤在内的多种癌症类型中，临床试验结果令人鼓舞，进一步加速了人们对这些新兴治疗模式的兴趣及其开发进程。As a result, the oncolytic virus therapy (OVT) pipeline is expanding rapidly, with companies such as 因此，溶瘤病毒疗法（OVT）的研发管线正在迅速扩张，诸如Genelux Genelux(Olvi-Vec), （奥尔维-维克）Candel Therapeutics 坎德尔治疗公司(CAN-2409), (CAN-2409),CG Oncology CG肿瘤学(cretostimogene grenadenorepvec), （克雷托刺激基因 格雷纳多雷普维克）Oncolytics Biotech Oncolytics Biotech(pelareorep), （佩拉雷奥雷普）Replimune Replimune(RP1), (RP1)，Lokon Pharma 洛康制药(LoAd703), (LoAd703),Imugene 伊姆基因(CF33), and (CF33)，以及SillaJen 希拉珍(Pexa-Vec [JX-594]) advancing candidates through clinical development. (Pexa-Vec [JX-594]) 推进候选药物通过临床开发。In parallel, SillaJen is progressing next-generation oncolytic immunotherapy candidates, including the SJ-600 and JX-900 series, further highlighting ongoing efforts to develop innovative virus-based treatments for cancer. 与此同时，SillaJen 正在推进下一代溶瘤免疫疗法候选药物（包括 SJ-600 和 JX-900 系列）的研发，进一步凸显了其在开发创新型病毒基癌症治疗手段方面的持续努力。Learn more about the hydroxychloroquine oncolytic virus cancer therapy@ 了解更多关于羟氯喹溶瘤病毒癌症疗法的信息 @Oncolytic Virus Analytics 溶瘤病毒分析Oncolytic Virus Cancer Therapy Competitive Landscape 溶瘤病毒癌症治疗竞争格局Some of the oncolytic viruses under development include 正在开发的一些溶瘤病毒包括Cretostimogene grenadenorepvec 克雷托刺激基因格雷纳登诺雷普韦克(CG Oncology), （CG Oncology）CAN-2409 CAN-2409(Candel Therapeutics), (Candel Therapeutics),AdAPT-001 AdAPT-001(EpicentRx), (EpicentRx)LOAd703 LOAd703(Lokon Pharma), （洛康制药）RP1 RP1(Replimune), (Replimune),VG 161 VG 161(Virogin Biotech), （Virogin Biotech），RP2 RP2(Replimune), (Replimune),BS001 BS001(Binhui Bio), （滨辉生物）Olvi-Vec 奥尔维-维克(Genelux), （Genelux）CF33 CF33(Imugene), （Imugene）BT-001 BT-001(BioInvent/Transgene), (BioInvent/Transgene),TG6050 TG6050(Transgene), （转基因）Pelareorep 佩拉雷奥普(Oncolytics Biotech), and others. （Oncolytics Biotech）等。Genelux's Genelux的Olvi-Vec 奥尔维-维克is a genetically modified vaccinia virus with a triple mechanism of action. It directly targets and destroys cancer cells, activates a tumor-specific immune response, and transforms the tumor microenvironment from an immunosuppressive 'cold' state into an immunoreactive 'hot' state. The therapy is currently under clinical development for several cancers, including platinum-resistant/refractory ovarian cancer, recurrent non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and pancreatic cancer. 是一种具有三重作用机制的基因改造痘苗病毒。它可直接靶向并摧毁癌细胞，激活肿瘤特异性免疫反应，并将肿瘤微环境从免疫抑制性的“冷”状态转化为免疫反应性的“热”状态。该疗法目前正处于针对多种癌症的临床开发阶段，包括铂类耐药/难治性卵巢癌、复发性非小细胞肺癌（NSCLC）、小细胞肺癌（SCLC）以及胰腺癌。In November 2023, Genelux announced that the US FDA had granted . 2023年11月，Genelux宣布美国食品药品监督管理局（FDA）已授予。Fast Track Designation (FTD) 快速通道认定（FTD）to olvi-vec for its development in patients with platinum-resistant/refractory ovarian cancer. 用于其在铂类耐药/难治性卵巢癌患者中的开发。CG Oncology's Cretostimogene CG Oncology 的 Cretostimogeneis an investigational oncolytic immunotherapy administered intravesically and is being studied in the 是一种经膀胱内给药的在研溶瘤免疫疗法，目前正在研究中Phase III BOND-003 trial BOND-003 三期临床试验for patients with Bacillus Calmette–Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). It is also being evaluated as a monotherapy in the Phase III PIVOT-006 trial for patients with intermediate-risk NMIBC. The US FDA has granted both 适用于对卡介苗（BCG）无反应的非肌层浸润性膀胱癌（NMIBC）患者。该药物还在针对中危NMIBC患者的III期PIVOT-006试验中作为单药疗法进行评估。美国食品药品监督管理局（FDA）已授予两者Fast Track Designation (FTD) and Breakthrough Therapy Designation (BTD) 快速通道认定（FTD）和突破性疗法认定（BTD）to cretostimogene grenadenorepvec for the treatment of high-risk, BCG-unresponsive NMIBC with carcinoma in situ, with or without Ta or T1 papillary tumors. 用于克雷托斯替莫金（cretostimogene）grenadenorepvec 治疗伴有或不伴有 Ta 或 T1 期乳头状肿瘤的、对卡介苗（BCG）无反应的高风险非肌层浸润性膀胱癌（NMIBC），且合并原位癌。BioInvent/Transgene's BT-001 BioInvent/Transgene 的 BT-001is a drug candidate being developed through a collaboration with French biotechnology company Transgene. It is an oncolytic virus engineered to deliver BioInvent's anti-CTLA-4 antibody directly within tumors. By releasing the antibody locally as the virus infects tumor cells, BT-001 is designed to enhance tumor-targeted activity while potentially reducing systemic side effects. BT-001 是一种正在与法国生物技术公司 Transgene 合作开发的候选药物。它是一种经过工程改造的溶瘤病毒，旨在将 BioInvent 的抗 CTLA-4 抗体直接递送至肿瘤内部。通过在病毒感染肿瘤细胞时局部释放抗体，BT-001 旨在增强针对肿瘤的活性，同时可能降低全身性副作用。The candidate is currently being investigated in combination with pembrolizumab in a Phase 1/2a clinical trial.. 该候选药物正在一项1/2a期临床试验中与帕博利珠单抗联合接受调查。The anticipated launch of these emerging therapies are poised to transform the oncolytic virus market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the oncolytic virus cancer therapymarket landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.. 这些新兴疗法的预期推出，有望在未来几年重塑溶瘤病毒市场的格局。随着这些前沿疗法不断成熟并获得监管批准，预计将重构溶瘤病毒癌症治疗市场的格局，树立新的护理标准，并为医疗创新和经济增长开辟机遇。To know more about oncolytic virus therapies developers companies, visit @ 如需了解更多关于溶瘤病毒疗法开发公司的信息，请访问 @Oncolytic Virus Landscape 溶瘤病毒格局Recent Developments in the Oncolytic Virus Cancer Therapy Market 溶瘤病毒癌症治疗市场的最新进展In 在August 2026, Replimune Group, Inc. 2026年8月，Replimune Group, Inc.announced that the FDA has granted accelerated approval to TUDRIQEVTM (vusolimogene oderparepvec-wtpg), formerly known as RP1, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease has progressed following treatment with an anti-PD-1 antibody-based regimen.. 宣布美国食品药品监督管理局（FDA）已加速批准TUDRIQEVTM（vusolimogene oderparepvec-wtpg，前称RP1）联合纳武利尤单抗，用于接受抗PD-1抗体方案治疗后疾病进展的不可切除晚期皮肤黑色素瘤成人患者。In 在July 2026, UroGen Pharma Ltd. 2026年7月，UroGen Pharma有限公司announced that the FDA has cleared its Investigational New Drug (IND) application for UGN-501, a next-generation investigational oncolytic virus. The IND clearance paves the way for the initiation of a planned Phase 1 clinical trial evaluating UGN-501 in patients with non-muscle invasive bladder cancer (NMIBC).. 宣布美国食品药品监督管理局（FDA）已批准其新一代在研溶瘤病毒UGN-501的新药临床试验（IND）申请。该IND获批为启动计划中的1期临床试验铺平了道路，该试验旨在评估UGN-501在非肌层浸润性膀胱癌（NMIBC）患者中的疗效和安全性。In 在June 2026, Candel Therapeutics, Inc. 2026年6月，Candel Therapeutics, Inc.initiated the global pivotal Phase 3 AURORA trial (NCT07660094) to evaluate aglatimagene besadenovec (aglatimagene; CAN-2409) plus valacyclovir alongside continued pembrolizumab treatment in patients with metastatic non-squamous NSCLC who experienced disease progression following pembrolizumab and platinum-based chemotherapy.. 启动了全球关键性III期AURORA试验（NCT07660094），以评估在既往接受帕博利珠单抗和含铂化疗后出现疾病进展的转移性非鳞状非小细胞肺癌患者中，阿格拉蒂马基因贝沙德诺韦（阿格拉蒂马基因；CAN-2409）联合伐昔洛韦并继续帕博利珠单抗治疗的疗效。In 在May 2026, CG Oncology 2026年5月，CG Oncologyreported positive Phase II CORE-008 Cohort CX results, with cretostimogene grenadenorepvec plus gemcitabine demonstrating encouraging high-grade event-free survival (HG-EFS), high complete response (CR) rates, and favorable tolerability in high-risk NMIBC patients. The data, which demonstrate encouraging HG-EFS, high CR rates, and a well-tolerated safety profile, were presented at the Society of Urologic Oncology (SUO) Session at the 2026 American Urological Association (AUA) Annual Meeting.. 报告了CORE-008研究CX队列的阳性II期结果，在高风险非肌层浸润性膀胱癌（NMIBC）患者中，cretostimogene grenadenorepvec联合吉西他滨显示出令人鼓舞的高级别无事件生存率（HG-EFS）、较高的完全缓解（CR）率以及良好的耐受性。这些数据展现了令人鼓舞的HG-EFS、高CR率以及良好的安全性特征，并在2026年美国泌尿协会（AUA）年会的泌尿肿瘤学会（SUO）专场上发表。In 在March 2026, Genelux 2026年3月，Geneluxreported positive clinical progress for Olvi-Vec, with Phase III ovarian cancer topline data expected in 2H26, encouraging lung cancer results, and cash runway extending into 1Q27. 报告称Olvi-Vec取得积极的临床进展，预计2026年下半年公布III期卵巢癌试验的顶线数据，肺癌试验结果令人鼓舞，现金跑道延长至2027年第一季度。In 在February 2026, CG Oncology 2026年2月，CG Oncologyreported accelerated enrollment and an expedited Phase III (PIVOT-006) timeline in intermediate-risk NMIBC, with topline data expected in 1H26. The company also reported strong efficacy and durability data for cretostimogene across high-risk NMIBC cohorts, announced upcoming Phase II combination results with gemcitabine, and remains on track for a BLA submission in high-risk BCG-unresponsive NMIBC during 2026.. 报告称，在中危非肌层浸润性膀胱癌（NMIBC）患者中，入组加速，III期临床试验（PIVOT-006）时间线提前，预计2026年上半年公布主要数据。该公司还报告了cretostimogene在高危NMIBC各队列中的强劲疗效和持久性数据，宣布即将公布与吉西他滨联合使用的II期临床试验结果，并计划在2026年提交针对高危BCG无应答NMIBC的生物制品许可申请（BLA），目前进展顺利。Oncolytic Virus Cancer Therapy Epidemiology Segmentation 溶瘤病毒癌症疗法的流行病学细分The oncolytic virus market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2022–2036 across the leading markets. Effective therapies for gastrointestinal cancers are scarce, with less than 溶瘤病毒市场报告是一份全面且专业的分析，为2022–2036年研究期间的主要市场提供深入的流行病学见解。胃肠道癌症的有效疗法稀缺，不足12% 百分之十二of pancreatic cancer patients surviving beyond five years with the current standard of care. 在当前标准治疗方案下，胰腺癌患者生存期超过五年的比例。The oncolytic virus cancer therapy target patient pool is segmented into: 溶瘤病毒癌症疗法的目标患者群体细分为：Total Cases of Selected Cancer Types 选定癌症类型的总病例数Target Patient Pool of OVTs by Cancer Types 按癌症类型划分的溶瘤病毒（OVT）目标患者池Treated Cases by Cancer Types 按癌症类型分类的治疗病例Oncolytic Virus Cancer Therapy Report Metrics 溶瘤病毒癌症治疗报告指标Details 详情Study Period 学习周期2022–2036 2022–2036Oncolytic Virus Cancer Therapy ReportCoverage 溶瘤病毒癌症治疗报告覆盖范围7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] 7MM [美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本]Key Indications Covered in the Report 报告中涵盖的关键适应症Melanoma, Biliary Tract Cancer, Head and Neck Cancer, Pancreatic Cancer, NSCLC, Hepatocellular Carcinoma, Breast Cancer, Prostate Cancer, Brain Cancer, Bladder Cancer, Ovarian Cancer, and others 黑色素瘤、胆道癌、头颈癌、胰腺癌、非小细胞肺癌、肝细胞癌、乳腺癌、前列腺癌、脑癌、膀胱癌、卵巢癌及其他Oncolytic Virus Therapies Market Size in 2025 2025年溶瘤病毒疗法市场规模USD 177 Million 1.77亿美元Key Oncolytic Virus Companies 主要溶瘤病毒公司CG Oncology, Candel Therapeutics, EpicentRx, Lokon Pharma, Replimune, Virogin Biotech, Binhui Bio, Genelux, Imugene, BioInvent, Transgene, Oncolytics Biotech, Amgen, Daiichi Sankyo, and others CG Oncology、Candel Therapeutics、EpicentRx、Lokon Pharma、Replimune、Virogin Biotech、宾会生物、Genelux、Imugene、BioInvent、Transgene、Oncolytics Biotech、安进、第一三共及其他公司KeyOncolytic Virus Cancer Therapy 关键溶瘤病毒癌症疗法Cretostimogene grenadenorepvec, CAN-2409, AdAPT-001, LOAd703, RP1, RP2, VG 161, BS001, Olvi-Vec, CF33, BT-001, TG6050, Pelareorep, IMLYGIC, DELYTACT, and others Cretostimogene grenadenorepvec、CAN-2409、AdAPT-001、LOAd703、RP1、RP2、VG 161、BS001、Olvi-Vec、CF33、BT-001、TG6050、Pelareorep、IMLYGIC、DELYTACT 等Scope of the 的范围Oncolytic Virus Cancer Therapy 溶瘤病毒癌症疗法Market Report 市场报告Oncolytic Virus Cancer Therapy Patient Population Forecast 溶瘤病毒癌症治疗患者人群预测Oncolytic Virus Cancer Therapy Therapeutics Market Size 溶瘤病毒癌症治疗药物市场规模Oncolytic Virus Cancer Therapy Pipeline Analysis 溶瘤病毒癌症治疗管线分析Oncolytic Virus Cancer Therapy Market Size and Trends 溶瘤病毒癌症治疗市场规模与趋势Oncolytic Virus Cancer Therapy Market Opportunity 溶瘤病毒癌症治疗市场机遇Oncolytic Virus Cancer Therapy Market Unmet Needs 溶瘤病毒癌症治疗市场的未满足需求KOL's Views on Oncolytic Virus Cancer Therapy 关键意见领袖对溶瘤病毒癌症疗法的观点Oncolytic Virus Cancer Therapy Market Access and Reimbursement 溶瘤病毒癌症疗法的市场准入与报销Discover the oncolytic virus manufacturing analytics @ 探索溶瘤病毒制造分析 @Oncolytic Virus Cancer Therapy Clinical Trials 溶瘤病毒癌症治疗临床试验Table of Contents 目录1 1Oncolytic Virus Cancer Therapy Market Key Insights 溶瘤病毒癌症治疗市场关键洞察2 2Oncolytic Virus Cancer Therapy Market Report Introduction 溶瘤病毒癌症治疗市场报告引言3 3Executive Summary of Oncolytic Virus Therapies 溶瘤病毒疗法执行摘要4 4Key Events 关键事件5 五Epidemiology and Market Forecast Methodology 流行病学与市场预测方法论6 6Oncolytic Virus Therapies Market Overview at a Glance in the 7MM 七国市场溶瘤病毒疗法概览6.1 6.1Market Share (%) Distribution by Therapies in 2025 2025年按疗法划分的市场份额（%）分布6.2 6.2Market Share (%) Distribution by Therapies in 2036 2036年按疗法划分的市场份额（%）分布7 7Background and Overview 背景与概述7.1 7.1Introduction 简介7.2 7.2Different Types of Oncolytic Viruses 溶瘤病毒的不同类型7.3 7.3Application of Oncolytic Viruses 溶瘤病毒的应用7.4 7.4Multiple Mechanisms of Action of OVTs for Cancer Therapy 溶瘤病毒疗法在癌症治疗中的多种作用机制7.5 7.5Routes of Administration 给药途径8 8Epidemiology and Target Patient Pool 流行病学与目标患者群体8.1 8.1Key Findings 主要发现8.2 8.2Assumptions and Rationale: 7MM 假设与理由：7MM8.3 8.3Epidemiology Scenario in the 7MM 七大主要市场（7MM）的流行病学情景8.3.1 8.3.1Target Patient Pool of OVTs by Cancer Types in the 7MM 七国市场（7MM）中按癌症类型划分的溶瘤病毒疗法（OVTs）目标患者群体8.4 8.4The United States 美国8.4.1 8.4.1Total Cases of Selected Cancer Types in the United States 美国选定癌症类型的总病例数8.4.2 8.4.2Target Patient Pool of OVTs by Cancer Types in the United States 美国按癌症类型划分的溶瘤病毒疗法目标患者群体8.4.3 8.4.3Treated Cases by Cancer Types in the United States 美国按癌症类型分类的病例治疗情况8.5 8.5EU4 and the UK 欧盟四国与英国8.6 8.6Japan 日本9 9Marketed Oncolytic Viruses 已上市的溶瘤病毒9.1 9.1Marketed Competitive Landscape of Oncolytic Virus Cancer Therapy (OVTs) 溶瘤病毒癌症疗法（OVTs）的市场竞争格局9.2 9.2IMLYGIC (talimogene laherparepvec): Amgen IMLYGIC（塔利莫金拉赫帕雷普韦克）：安进9.2.1 9.2.1Product Description 产品描述9.2.2 9.2.2Regulatory Milestones 监管里程碑9.2.3 9.2.3Others Developmental Activities 其他发展活动9.2.4 9.2.4Ongoing Clinical Developmental Activities 正在进行的临床开发活动9.2.4.1 9.2.4.1Clinical Trial Information 临床试验信息9.2.5 9.2.5Safety and Efficacy 安全性与有效性9.2.6 9.2.6Analyst Views 分析师观点9.3 9.3DELYTACT (G47Δ): Daiichi Sankyo DELYTACT（G47Δ）：第一三共10 10Emerging Oncolytic Viruses 新兴溶瘤病毒10.1 10.1Emerging Competitive Landscape of Oncolytic Virus Cancer Therapy (OVTs) 溶瘤病毒癌症疗法（OVTs）新兴的竞争格局10.2 10.2Olvi-Vec: Genelux Olvi-Vec：Genelux10.2.1 10.2.1Product Description 产品描述10.2.2 10.2.2Other Developmental Activity 其他发展活动10.2.3 10.2.3Clinical Developmental Activities 临床开发活动10.2.3.1 10.2.3.1Clinical Trial Information 临床试验信息10.2.4 10.2.4Safety and Efficacy 安全性与有效性10.2.5 10.2.5Analyst Views 分析师观点10.3 10.3CAN-2409: Candel Therapeutics CAN-2409：Candel Therapeutics10.4 10.4RP1: Replimune RP1：Replimune10.5 10.5Pelareorep: Oncolytics Biotech 佩拉雷奥普：Oncolytics Biotech10.6 10.6Cretostimogene grenadenorepvec: CG Oncology 克雷托刺激基因格雷纳多诺雷普韦克：CG肿瘤公司10.7 10.7CAN-3110: Candel Therapeutics CAN-3110：Candel Therapeutics10.8 10.8LoAd703: Lokon Pharma LoAd703：洛康制药10.9 10.9CF33: Imugene CF33：ImugeneList to be continued… 列表待续……11 十一Oncolytic Virus Market: 7MM analysis 溶瘤病毒市场：七大主要市场分析11.1 11.1Key Findings 主要发现11.2 11.2Oncolytic Virus Cancer Therapy Market Outlook 溶瘤病毒癌症治疗市场展望11.3 11.3Conjoint Analysis 联合分析11.4 11.4Key Oncolytic Virus Cancer Therapy Market Forecast Assumptions 关键溶瘤病毒癌症治疗市场预测假设11.5 11.5Market Size by Indications in the 7MM 七国市场按适应症划分的市场规模11.6 11.6Market Size by Therapies in the 7MM 七大主要市场按疗法划分的市场规模11.7 11.7United States Oncolytic Virus Cancer Therapy Market Size 美国溶瘤病毒癌症治疗市场规模11.7.1 11.7.1Market Size by Indications in the US 美国按适应症划分的市场规模11.7.2 11.7.2Market Size by Therapies in the US 美国按疗法划分的市场规模11.8 11.8EU4 and the UK Oncolytic Virus Cancer Therapy Market Size 欧盟四国及英国溶瘤病毒癌症治疗市场规模11.9 11.9Japan Oncolytic Virus Cancer Therapy Market Size 日本溶瘤病毒癌症治疗市场规模12 十二Unmet Needs 未满足的需求13 13SWOT Analysis SWOT分析14 14KOL Views KOL观点15 十五Market Access and Reimbursement 市场准入与报销15.1 15.1United States 美国15.2 15.2EU4 and the UK 欧盟四国与英国15.3 15.3Japan 日本15.4 15.4Summary and Comparison of Market Access and Pricing Policy Developments in 2025 2025年市场准入与定价政策发展综述及比较15.5 15.5Oncolytic Virus Therapies: Market Access and Reimbursement 溶瘤病毒疗法：市场准入与报销16 十六Bibliography 参考文献17 十七Oncolytic Virus Cancer Therapy Market Report Methodology 溶瘤病毒癌症治疗市场报告方法论Related Reports 相关报告Oncolytic Virus Competitive Landscape 溶瘤病毒竞争格局Oncolytic Virus Competitive Landscape – 2026 溶瘤病毒竞争格局 – 2026report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key oncolytic virus companies, including 本报告提供关于管线格局、管线药物概况（包括临床和非临床阶段产品）以及关键溶瘤病毒公司的全面洞察，包括Genelux Corporation, Candel Therapeutics, CG Oncology, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Virogin Biotech, Replimune, Viralytics, Oncolys Biopharma, Istari Oncology, Immvira Pharma, Seneca Therapeutics, Treovir, LLC, Targovax, Lokon Pharma, ORCA Therapeutics, Beijing SyngenTech, ViruCure, Tasly Pharmaceuticals, Turnstone Biologics, BioInvent, Transgene, Elicera Therapeutics, Orgenesis, Virttu Biologics, Imugene, Astellas Pharma, Wuhan Binhui Biotechnology Co., Ltd., Mustang Bio, Virogin Biotech, Vaxiion Therapeutics, ImmVirX, Memgen, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, VCN Biosciences, Candel therapeutics, Sorrento Therapeutics, Imugene Limited, Calidi Biotherapeutics, Replimune, TILT Biotherapeutics, Guangzhou Virotech Pharmaceutical, DNAtrix, Oncorus, BioEclipse Therapeutics. Genelux公司、Candel Therapeutics、CG Oncology、DNAtrix、SillaJen Biotherapeutics、Oncolytics Biotech、武汉滨辉生物科技、Oryx GmbH、江苏信诺达生物医药有限公司、Virogin Biotech、Replimune、Viralytics、Oncolys Biopharma、Istari Oncology、Immvira Pharma、Seneca Therapeutics、Treovir, LLC、Targovax、Lokon Pharma、ORCA Therapeutics、北京赛金科技、ViruCure、天士力医药、Turnstone Biologics、BioInvent、Transgene、Elicera Therapeutics、Orgenesis、Virttu Biologics、Imugene、安斯泰来制药、武汉滨辉生物科技有限公司、Mustang Bio、Virogin Biotech、Vaxiion Therapeutics、ImmVirX、Memgen、Replimune、Immvira Pharma、ViroCure、GeneMedicine、PsiOxus Therapeutics、VCN Biosciences、Candel Therapeutics、Sorrento Therapeutics、Imugene Limited、Calidi Biotherapeutics、Replimune、TILT Biotherapeutics、广州唯思康药业、DNAtrix、Oncorus、BioEclipse Therapeutics。, and others. ，以及其他。Non-Small Cell Lung Cancer 非小细胞肺癌Market 市场Non-Small Cell Lung Cancer 非小细胞肺癌Market Insights, Epidemiology, and Market Forecast 市场洞察、流行病学及市场预测– –2036 2036report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies including 本报告深入解析了该疾病、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和包括以下在内的关键非小细胞肺癌（NSCLC）企业：BeiGene 百济神州, Merus and Partner Therapeutics, Johnson & Johnson Innovative Medicine, Betta Pharma, Xcovery, CStone Pharmaceuticals, Bristol-Myers Squibb, Haihe Biopharma, Taiho Pharmaceutical, Takeda Pharmaceuticals, EMD Serono (Merck KGaA), Eli Lilly and Company, Merck, Regeneron, Sanofi, Ono Pharmaceutical, Novartis, Genentech, Roche, Amgen, Chugai Laboratories, Moderna Therapeutics, Pfizer, GSK . 、Merus和Partner Therapeutics、强生创新药物、贝达药业、Xcovery、基石药业、百时美施贵宝、海河生物制药、大正制药、武田制药、EMD Serono（默克KGaA）、礼来公司、默沙东、再生元、赛诺菲、小野制药、诺华、基因泰克、罗氏、安进、中外实验室、Moderna Therapeutics、辉瑞、葛兰素史克。and others. 以及其他。Melanoma Market 黑色素瘤市场Melanoma 黑色素瘤Market Insights, Epidemiology, and Market Forecast – 2036 市场洞察、流行病学及市场预测 – 2036report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key melanomacompanies including 报告深入解析了该疾病、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和关键黑色素瘤公司，包括IO Biotech, Merck Sharp & Dohme, Eisai, Regeneron Pharmaceuticals, Iovance Biotherapeutics, Highlight Therapeutics, Linnaeus Therapeutics, Spring Bank Pharmaceuticals, Taiga Biotechnologies, Inc., Aivita Biomedical, Inc., Genentech, Inc., Dana-Farber Cancer Institute, BioMed Valley Discoveries, Inc, Amgen, Checkmate Pharmaceuticals, Astellas Pharma Inc, Galectin Therapeutics Inc., Eucure (Beijing) Biopharma Co., Ltd, Mologen AG, Ultimovacs ASA, Seagen Inc., MedImmune LLC, OnKure, Inc., Syntrix Biosystems, Inc., Anaveon AG, iOx Therapeutics, Portage Biotech, ModernaTX, Inc., Nektar Therapeutics, BioNTech SE, Sapience Therapeutics, HUYABIO International, LLC., Provectus Biopharmaceuticals, Inc., Cantargia AB, Turnstone Biologics, Corp., Aura Biosciences, F-star Therapeutics, Inc., Day One Biopharmaceuticals, Inc., Kinnate Biopharma, Xencor, Inc., HiFiBiO Therapeutics. IO Biotech、默沙东（Merck Sharp & Dohme）、卫材（Eisai）、再生元制药（Regeneron Pharmaceuticals）、Iovance Biotherapeutics、Highlight Therapeutics、Linnaeus Therapeutics、Spring Bank Pharmaceuticals、Taiga Biotechnologies, Inc.、Aivita Biomedical, Inc.、基因泰克（Genentech, Inc.）、丹娜法伯癌症研究所（Dana-Farber Cancer Institute）、BioMed Valley Discoveries, Inc.、安进（Amgen）、Checkmate Pharmaceuticals、安斯泰来制药（Astellas Pharma Inc.）、Galectin Therapeutics Inc.、欧凯雷（北京）生物科技有限公司（Eucure (Beijing) Biopharma Co., Ltd）、Mologen AG、Ultimovacs ASA、Seagen Inc.、MedImmune LLC、OnKure, Inc.、Syntrix Biosystems, Inc.、Anaveon AG、iOx Therapeutics、Portage Biotech、ModernaTX, Inc.、Nektar Therapeutics、BioNTech SE、Sapience Therapeutics、HUYABIO International, LLC.、Provectus Biopharmaceuticals, Inc.、Cantargia AB、Turnstone Biologics, Corp.、Aura Biosciences、F-star Therapeutics, Inc.、Day One Biopharmaceuticals, Inc.、Kinnate Biopharma、Xencor, Inc.、HiFiBiO Therapeutics。, ，and others. 以及其他。Pancreatic Cancer Market 胰腺癌市场Pancreatic Cancer 胰腺癌Market Insights, Epidemiology, and Market Forecast – 2036 市场洞察、流行病学及市场预测 – 2036年report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pancreatic cancercompanies including 报告提供对疾病的深入理解、历史及预测的流行病学数据，以及市场趋势、市场驱动因素、市场壁垒和关键的胰腺癌公司，包括FibroGen, OSE Immunotherapeutics, Lokon Pharma, Oncotelic Inc., Tesaro, Inc., Helix BioPharma Corporation, Theradex, Tvardi Therapeutics, Incorporated, AIM ImmunoTech Inc., BioNTech SE, Prestige Biopharma Limited, HCW Biologics, Cantex Pharmaceuticals, XBiotech, Inc., Lumicell, Inc., CARsgen Therapeutics Co., Ltd., Panbela Therapeutics, Inc.. FibroGen、OSE Immunotherapeutics、Lokon Pharma、Oncotelic Inc.、Tesaro, Inc.、Helix BioPharma Corporation、Theradex、Tvardi Therapeutics, Incorporated、AIM ImmunoTech Inc.、BioNTech SE、Prestige Biopharma Limited、HCW Biologics、Cantex Pharmaceuticals、XBiotech, Inc.、Lumicell, Inc.、合源生物技术有限公司（CARsgen Therapeutics Co., Ltd.）、Panbela Therapeutics, Inc., ，and others. 等等。About 关于DelveInsight DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve. DelveInsight 是一家领先的商业咨询和市场研究公司，专注于生命科学领域。它通过提供全面的端到端解决方案，帮助制药公司提升绩效。通过我们基于订阅的平台 PharmDelve，您可以轻松获取所有医疗保健和制药市场研究报告。. 。Contact Us 联系我们Shruti Thakur 什鲁蒂·塔库尔[emailprotected] [email protected]+14699457679 +14699457679SOURCE DelveInsight Business Research, LLP 来源：DelveInsight Business Research, LLP21 二十一% 百分比more press release views with 更多新闻稿浏览量Request a Demo 申请演示

SAN DIEGO, Aug. 18, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced the election of Dannielle Appelhans to its Board of Directors. Ms. Appelhans brings more than 20 years of executive leadership across the biotechnology and pharmaceutical industries, with deep expertise in operations, manufacturing, and supply chain management. "Dannielle brings a rare combination of operational excellence and manufacturing depth that aligns directly with our growth strategy, and we are delighted to welcome her to the Halozyme board," said Dr. Helen Torley, President and Chief Executive Officer. "As we continue to scale ENHANZE as a compounding platform engine and advance Hypercon and Surf Bio, her experience transforming global operations and executing major partnerships will be a tremendous asset as we deliver on our growth strategy and create meaningful new value for our partners, patients, and shareholders." Ms. Appelhans has served as President and Chief Executive Officer of COUR Pharmaceuticals, a private biotechnology company developing platform-based therapies for autoimmune diseases, since 2023. Under her leadership, the company negotiated and executed a strategic collaboration with Genentech with a potential value of up to $1 billion. Previously, she served as Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded, clinical-stage biopharmaceutical company. Earlier, she held roles of increasing responsibility at Novartis, culminating as Senior Vice President and Chief Technical Officer of Novartis Gene Therapies, where she led development, manufacturing, and supply chain for the gene therapy unit, including the approved therapy Zolgensma, and as Senior Vice President, Global Head of Supply Chain Management. She began her career at McKinsey & Company and Eli Lilly and Company, and previously served on the Board of Directors of Generation Bio Co. "I am honored to join Halozyme's Board of Directors," said Ms. Appelhans. "Halozyme has built a differentiated, royalty-driven business and a compelling strategy for durable growth through its multiple drug delivery technology platforms. I look forward to working with the board and leadership team to help deliver even greater value to patients and shareholders." Ms. Appelhans earned a Master of Science in mechanical engineering from Massachusetts Institute of Technology's School of Engineering, an MBA from Massachusetts Institute of Technology's Sloan School of Management, and a Bachelor of Science in mechanical engineering from the University of Michigan. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V., Skye Bioscience, GSK and Incyte. Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at-home and healthcare-provider settings. The addition of Surf Bio's polymer-based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE® by enabling creation and delivery of highly concentrated biologics. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx, Vertex Pharmaceuticals, and Oruka Therapeutics. Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility. Forward-Looking Statements This press release may include forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential and statements regarding future performance and growth of Halozyme's business. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", "will be" and similar expressions. Although Halozyme believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme, that could cause actual results and developments to differ materially from those expressed in the forward-looking information and statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Halozyme undertakes no obligation to update or revise any forward-looking statements or any other information contained herein. Contacts: Tram Bui VP, Investor Relations and Corporate Communications 609-333-7668 [email protected] Sydney Charlton Teneo 917-972-8407 [email protected] SOURCE Halozyme Therapeutics, Inc. 21% more press release views with Request a Demo